Vera Therapeutics, Inc.
VERA
$36.70
$0.090.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.12M | 34.90M | 27.46M | 21.95M | 15.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.13M | 94.21M | 83.93M | 80.14M | 57.19M |
| Operating Income | -125.13M | -94.21M | -83.93M | -80.14M | -57.19M |
| Income Before Tax | -121.03M | -91.10M | -80.29M | -76.53M | -51.69M |
| Income Tax Expenses | -- | 1.00K | -- | -- | -- |
| Earnings from Continuing Operations | -121.03M | -91.10M | -80.29M | -76.53M | -51.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.03M | -91.10M | -80.29M | -76.53M | -51.69M |
| EBIT | -125.13M | -94.21M | -83.93M | -80.14M | -57.19M |
| EBITDA | -124.99M | -94.07M | -83.80M | -80.02M | -57.11M |
| EPS Basic | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 |
| Normalized Basic EPS | -1.05 | -0.87 | -0.79 | -0.75 | -0.51 |
| EPS Diluted | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 |
| Normalized Diluted EPS | -1.05 | -0.87 | -0.79 | -0.75 | -0.51 |
| Average Basic Shares Outstanding | 71.48M | 65.63M | 63.85M | 63.79M | 63.67M |
| Average Diluted Shares Outstanding | 71.48M | 65.63M | 63.85M | 63.79M | 63.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |